Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer-Reference-Cited by-同舟云学术

Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer

Published:2021-08-20 Issue:20 Volume:10 Page:6971-6984
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Imai Hisao¹²^ORCID,Kishikawa Takayuki³^ORCID,Minemura Hiroyuki⁴^ORCID,Yamada Yutaka⁵^ORCID,Ibe Tatsuya⁶,Yamaguchi Ou¹^ORCID,Mouri Atsuto¹,Hamamoto Yoichiro⁶,Kanazawa Kenya⁴,Kasai Takashi³^ORCID,Kaira Kyoichi¹^ORCID,Kaburagi Takayuki⁵,Minato Koichi²,Kobayashi Kunihiko¹,Kagamu Hiroshi¹

Affiliation:

1. Department of Respiratory Medicine Comprehensive Cancer Center International Medical Center Saitama Medical University Hidaka Saitama Japan

2. Division of Respiratory Medicine Gunma Prefectural Cancer Center Ota Gunma Japan

3. Division of Thoracic Oncology Tochigi Cancer Center Utsunomiya Tochigi Japan

4. Department of Pulmonary Medicine Fukushima Medical University Fukushima Japan

5. Division of Respiratory Medicine Ibaraki Prefectural Central Hospital Kasama Ibaraki Japan

6. Department of Pulmonary Medicine National Hospital OrganizationNishisaitama‐Chuo National Hospital Tokorozawa Saitama Japan

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4220

Reference44 articles.

1. Cancer treatment and survivorship statistics, 2019

2. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

3. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer

4. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study

5. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance of LAT1 expression in pleural mesothelioma;Heliyon;2024-09

2. Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data;Discover Oncology;2024-07-24

3. Effect of body mass index and cholesterol‐rich apolipoprotein‐B‐containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors‐based therapy: A retrospective analysis;Cancer Medicine;2024-05-31

4. Comparison of Efficacy, safety, and cost-effectiveness of pembrolizumab versus chemotherapy for patients with advanced non-small cell lung cancer: a real-world study;2024-04-25

5. Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy;Oncology Letters;2024-01-19